{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T02:34:58Z","timestamp":1750818898013,"version":"3.37.3"},"reference-count":31,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Children with skeletal dysplasias have not been consistently managed by pediatric endocrinologists despite the recognized expertise of these practitioners in managing genetic growth disorders. Growth-altering treatments have broadened the role of the pediatric endocrinologist to manage and sometimes become primary coordinators for genetic disorders such as Turner syndrome and Prader-Willi syndrome. We illustrate how recent advances in understanding the pathophysiology of skeletal disorders and the development of targeted treatments provide an opportunity for pediatric endocrinologists to further expand their role in managing certain skeletal dysplasias, including achondroplasia.<\/jats:p>","DOI":"10.1210\/clinem\/dgad726","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T18:00:15Z","timestamp":1702317615000},"page":"e1410-e1414","source":"Crossref","is-referenced-by-count":1,"title":["What Is the Role for Pediatric Endocrinologists in the Management of Skeletal Dysplasias?"],"prefix":"10.1210","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8775-6481","authenticated-orcid":false,"given":"Nadia","family":"Merchant","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Diabetes, Children's National Hospital , Washington, DC 20010 , USA"},{"name":"Department of Pediatrics, George Washington University School of Medicine and Health Sciences , Washington, DC 20037 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynda E","family":"Polgreen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center , Torrance, CA 90502 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron G","family":"Rosenfeld","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Oregon Health & Science University , Portland, OR 97239 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"author":"Subspecialties CoP","key":"2024041923075986700_dgad726-B1"},{"key":"2024041923075986700_dgad726-B2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000381051","article-title":"Skeletal dysplasias: an overview","volume":"28","author":"Offiah","year":"2015","journal-title":"Endocr Dev"},{"issue":"3","key":"2024041923075986700_dgad726-B3","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0430","article-title":"Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 cincinnati international turner syndrome meeting","volume":"177","author":"Gravholt","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2024041923075986700_dgad726-B4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/ajmg.c.31680","article-title":"Growth and growth hormone in Turner syndrome: looking back, looking ahead","volume":"181","author":"Los","year":"2019","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"10","key":"2024041923075986700_dgad726-B5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41574-019-0224-4","article-title":"Turner syndrome: mechanisms and management","volume":"15","author":"Gravholt","year":"2019","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"2024041923075986700_dgad726-B6","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1136\/adc.60.10.932","article-title":"Growth curve for girls with Turner syndrome","volume":"60","author":"Lyon","year":"1985","journal-title":"Arch Dis Child"},{"author":"The Turner Syndrome Society of the United States","key":"2024041923075986700_dgad726-B7"},{"issue":"1","key":"2024041923075986700_dgad726-B8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1542\/peds.2010-2820","article-title":"Clinical report\u2014health supervision for children with Prader-Willi syndrome","volume":"127","author":"McCandless","year":"2011","journal-title":"Pediatrics"},{"issue":"1","key":"2024041923075986700_dgad726-B9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/gim.0b013e31822bead0","article-title":"Prader-Willi syndrome","volume":"14","author":"Cassidy","year":"2012","journal-title":"Genet Med"},{"issue":"1","key":"2024041923075986700_dgad726-B10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.tem.2003.11.003","article-title":"Prader-Willi syndrome: advances in genetics, pathophysiology and treatment","volume":"15","author":"Goldstone","year":"2004","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"2024041923075986700_dgad726-B11","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1210\/jcem.87.4.8414","article-title":"Benefits of long-term GH therapy in prader-willi syndrome: a 4-year study","volume":"87","author":"Carrel","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2024041923075986700_dgad726-B12","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1515\/jpem-2001-0805","article-title":"Sustained benefits of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome are dose-dependent","volume":"14","author":"Carrel","year":"2001","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"5","key":"2024041923075986700_dgad726-B13","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1210\/jc.2002-021536","article-title":"Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome","volume":"88","author":"Haqq","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024041923075986700_dgad726-B14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/jcpp.12601","article-title":"Cognitive and adaptive advantages of growth hormone treatment in children with Prader-Willi syndrome","volume":"58","author":"Dykens","year":"2017","journal-title":"J Child Psychol Psychiatry"},{"issue":"4","key":"2024041923075986700_dgad726-B15","doi-asserted-by":"crossref","first-page":"274","DOI":"10.21037\/tp.2017.09.04","article-title":"Review of Prader-Willi syndrome: the endocrine approach","volume":"6","author":"Heksch","year":"2017","journal-title":"Transl Pediatr"},{"issue":"6","key":"2024041923075986700_dgad726-B16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/GIM.0b013e3181daae9b","article-title":"The skeletal dysplasias","volume":"12","author":"Krakow","year":"2010","journal-title":"Genet Med"},{"key":"2024041923075986700_dgad726-B17","doi-asserted-by":"crossref","first-page":"115872","DOI":"10.1016\/j.bone.2021.115872","article-title":"Lifetime impact of achondroplasia: current evidence and perspectives on the natural history","volume":"146","author":"Hoover-Fong","year":"2021","journal-title":"Bone"},{"key":"2024041923075986700_dgad726-B18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/TACG.S51485","article-title":"Optimal management of complications associated with achondroplasia","volume":"7","author":"Ireland","year":"2014","journal-title":"Appl Clin Genet"},{"author":"U.S. Food & Drug Administration","key":"2024041923075986700_dgad726-B19"},{"issue":"9-10","key":"2024041923075986700_dgad726-B20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000520812","article-title":"Evolution and future of growth plate therapeutics","volume":"94","author":"Allen","year":"2021","journal-title":"Horm Res Paediatr"},{"issue":"10252","key":"2024041923075986700_dgad726-B21","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0140-6736(20)31541-5","article-title":"Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial","volume":"396","author":"Savarirayan","year":"2020","journal-title":"Lancet"},{"issue":"12","key":"2024041923075986700_dgad726-B22","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/s41436-021-01287-7","article-title":"Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study","volume":"23","author":"Savarirayan","year":"2021","journal-title":"Genet Med"},{"issue":"Suppl 1","key":"2024041923075986700_dgad726-B23","doi-asserted-by":"crossref","first-page":"A591","DOI":"10.1210\/jendso\/bvac150.1225","article-title":"LBMON196 a randomized controlled trial of vosoritide in infants and toddlers with achondroplasia","volume":"6","author":"Savarirayan","year":"2022","journal-title":"J Endocr Soc"},{"author":"BioMarin Pharmaceutical","key":"2024041923075986700_dgad726-B24"},{"issue":"5","key":"2024041923075986700_dgad726-B25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/14728222.2022.2077722","article-title":"Emerging drug targets for achondroplasia","volume":"26","author":"Savarirayan","year":"2022","journal-title":"Expert Opin Ther Targets"},{"issue":"3","key":"2024041923075986700_dgad726-B26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1124\/jpet.119.258251","article-title":"TransCon CNP, a sustained-release c-type natriuretic peptide prodrug, a potentially safe and efficacious new therapeutic modality for the treatment of comorbidities associated with fibroblast growth factor receptor 3-related skeletal dysplasias","volume":"370","author":"Breinholt","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"2024041923075986700_dgad726-B27","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.1111\/bcp.15369","article-title":"Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long-acting C-type natriuretic peptide prodrug, TransCon CNP","volume":"88","author":"Breinholt","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2024041923075986700_dgad726-B28","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1172\/JCI83926","article-title":"Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model","volume":"126","author":"Komla-Ebri","year":"2016","journal-title":"J Clin Invest"},{"key":"2024041923075986700_dgad726-B29","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221084848","article-title":"Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies","volume":"14","author":"Savarirayan","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"7802","key":"2024041923075986700_dgad726-B30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/d41586-020-01034-z","article-title":"Inclusive science: ditch insensitive terminology","volume":"580","author":"Baeckens","year":"2020","journal-title":"Nature"},{"issue":"1549","key":"2024041923075986700_dgad726-B31","first-page":"26","article-title":"Deaf community views on paediatric cochlear implantation","volume":"135","author":"Putnam","year":"2022","journal-title":"N Z Med J"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad726\/54640318\/dgad726.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/5\/e1410\/57285925\/dgad726.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/5\/e1410\/57285925\/dgad726.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T23:09:55Z","timestamp":1713568195000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/5\/e1410\/7468983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,12,11]]},"published-print":{"date-parts":[[2024,4,19]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad726","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"type":"print","value":"0021-972X"},{"type":"electronic","value":"1945-7197"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2023,12,11]]}}}